Literature DB >> 22939812

Mean platelet volume and β-thromboglobulin levels in familial Mediterranean fever: effect of colchicine use?

Gul Babacan Abanonu1, Alper Daskin, Mehmet Fatih Akdogan, Seyit Uyar, Refik Demirtunc.   

Abstract

BACKGROUND: Many studies have shown that subclinical inflammation persisted during remission period of Familial Mediterranean Fever (FMF) patients but long term effects of subclinical inflammation in these patients aren't clearly known. Besides, a few of the recent studies revealed that risk of atherosclerosis had increased in FMF patients. β-Thromboglobulin (β-TG) is considered as a sensitive marker of platelet activation. In this study Mean Platelet Volume (MPV) and β-TG levels were evaluated in FMF patients.
METHODS: Following the Local Ethics Committee's consent, 25 FMF patients were included in the study. Twenty eight age and sex matched healthy volunteers were recruited as a control group. Lipid profile, inflammatory parameters, hemogram, β-TG, MPV were assessed. Statistical analysis was performed with SPSS for Windows 16.00.
RESULTS: Group I consisted of 25 FMF cases (16 females, 9 males; mean age: 35.72 ± 12.34 years), Group II consisted of 28 cases (22 females, 6 males; mean age 31.78 ± 10.31 years). There was no statistically significant difference between the groups in terms of age and gender distribution, smoking status, total cholesterol, triglyceride, LDL and MPV (p>0.05). HDL levels were found to be statistically lower in Group I (p:0.04). Median β-TG levels was significantly higher in Group II than Group I (129.50 (range:372.00) ng/mL versus 104.00 (range:212.80) ng/mL respectively; p:0.03).
CONCLUSION: In this study MPV and β-TG were evaluated for FMF cases and healthy controls, β-TG levels were found significantly lower among patients; we hypothesized that this difference may have resulted from the effect of colchicine use on platelet functions.
Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22939812     DOI: 10.1016/j.ejim.2012.04.007

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

1.  Effect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy Subjects.

Authors:  Binita Shah; Nicole Allen; Bhisham Harchandani; Michael Pillinger; Stuart Katz; Steven P Sedlis; Christina Echagarruga; Svetlana Krasnokutsky Samuels; Pajazit Morina; Prabhjot Singh; Liza Karotkin; Jeffrey S Berger
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

2.  Evaluation of the mean platelet volume in secondary amyloidosis due to familial Mediterranean fever.

Authors:  Nihal Ozkayar; Serhan Piskinpasa; Fatma Akyel; Fatih Dede; Tolga Yildirim; Didem Turgut; Eyup Koc; Ibrahim C Haznedaroglu
Journal:  Rheumatol Int       Date:  2013-05-15       Impact factor: 2.631

Review 3.  Colchicine--Update on mechanisms of action and therapeutic uses.

Authors:  Ying Ying Leung; Laura Li Yao Hui; Virginia B Kraus
Journal:  Semin Arthritis Rheum       Date:  2015-06-26       Impact factor: 5.532

4.  Plasma Metabolic Signature of Atherosclerosis Progression and Colchicine Treatment in Rabbits.

Authors:  Mario Augusto Izidoro; Alberto Cecconi; María Isabel Panadero; Jesús Mateo; Joanna Godzien; Jean Paul Vilchez; Ángeles López-Gonzálvez; Jesús Ruiz-Cabello; Borja Ibañez; Coral Barbas; Francisco J Rupérez
Journal:  Sci Rep       Date:  2020-04-27       Impact factor: 4.379

Review 5.  The Role of Colchicine in Atherosclerosis: From Bench to Bedside.

Authors:  Leticia González; Juan Francisco Bulnes; María Paz Orellana; Paula Muñoz Venturelli; Gonzalo Martínez Rodriguez
Journal:  Pharmaceutics       Date:  2022-07-01       Impact factor: 6.525

Review 6.  Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.

Authors:  Fan-Shun Zhang; Qing-Ze He; Chengxue Helena Qin; Peter J Little; Jian-Ping Weng; Suo-Wen Xu
Journal:  Acta Pharmacol Sin       Date:  2022-01-19       Impact factor: 7.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.